CAJ | 학술논문

目的：探讨厄洛替尼治疗终末期（PS 评分≥3分）非小细胞肺癌的疗效。方法终末期非小细胞肺癌患者47例，随机分为2组，治疗组25例接受厄洛替尼治疗，对照组22例不接受厄洛替尼治疗和其他放化疗，只接受营养支持、控制疼痛、缓解症状等治疗。观察2组的临床疗效、不良反应、生存期及预后影响因素。结果治疗组疾病控制率为72．0％（18/25），高于对照组的27．3％（6/22），差异有统计学意义（ P ﹤0．01）；治疗组不良反应皮疹发生率84．0％（21/25），腹泻发生率40．0％（10/25），厌食发生率12．0％（3/25），对照组无不良反应。中位生存期治疗组92 d，对照组61 d，差异有统计学意义（ P ＜0．01）。 Cox 分析表明，性别、年龄、既往化疗次数和化疗方案对疗效影响不大，而病理分型、EGFR 突变情况和吸烟史是疗效的影响因素（ P ＜0．05）。结论厄洛替尼可延长终末期非小细胞肺癌患者的生存期，提高疾病控制率。
목적：탐토액락체니치료종말기（PS 평분≥3분）비소세포폐암적료효。방법종말기비소세포폐암환자47례，수궤분위2조，치료조25례접수액락체니치료，대조조22례불접수액락체니치료화기타방화료，지접수영양지지、공제동통、완해증상등치료。관찰2조적림상료효、불량반응、생존기급예후영향인소。결과치료조질병공제솔위72．0％（18/25），고우대조조적27．3％（6/22），차이유통계학의의（ P ﹤0．01）；치료조불량반응피진발생솔84．0％（21/25），복사발생솔40．0％（10/25），염식발생솔12．0％（3/25），대조조무불량반응。중위생존기치료조92 d，대조조61 d，차이유통계학의의（ P ＜0．01）。 Cox 분석표명，성별、년령、기왕화료차수화화료방안대료효영향불대，이병리분형、EGFR 돌변정황화흡연사시료효적영향인소（ P ＜0．05）。결론액락체니가연장종말기비소세포폐암환자적생존기，제고질병공제솔。
Objective To investigate the effect of erlotinib in treatment of end -stage (PS score ≥ 3 points) non-small cell lung cancer.Methods 47 cases of end-stage non-small cell lung cancer patients were randomly divided into two groups, treatment group of 25 patients who received erlotinib treatment , the control group with 22 cases are not accepted erlo-tinib therapy and other chemotherapy , only accept nutritional support , control pain, relieve symptoms treatment.The clinical efficacy of the two groups, adverse reactions, survival and prognostic factors were observed .Results The disease control rate was 72.0% (18 /25) in treatment group which is higher than 27.3% (6 /22) in the control group, the difference was statisti-cally significant ( P <0.01); in treatment group, the incidence of rash reaction was 84.0% (21 /25) , the incidence of di-arrhea was 40.0% (10 /25), anorexia incidence was 12.0% (3 /25), the control group had no adverse reactions .The medi-an survival in the treatment group was 92 d, control group was 61 d ( P <0.01).Cox analysis showed that gender , age, number of previous chemotherapy and type of chemotherapy had little effect on the efficacy , and pathological type, EGFR mu-tation status and smoking history is curative factors ( P <0.05).Conclusion Erlotinib prolongs survival of end-stage non-small cell lung cancer patients and improve disease control rate .